[1]王道元,乔保平#,孙如坤,等.前列腺特异性抗原相关变数与前列腺癌Gleason评分及临床分期的关系[J].郑州大学学报(医学版),2012,(04):537.
 WANG Daoyuan,QIAO Baoping,SUN Rukun,et al.Relationship between prostate specific antigen related variables and Gleason score and clinical stage of prostate cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(04):537.
点击复制

前列腺特异性抗原相关变数与前列腺癌Gleason评分及临床分期的关系
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2012年04期
页码:
537
栏目:
应用研究
出版日期:
2012-07-20

文章信息/Info

Title:
Relationship between prostate specific antigen related variables and Gleason score and clinical stage of prostate cancer
作者:
王道元乔保平#孙如坤辛航王雷阳
郑州大学第一附属医院泌尿外科 郑州 450052
Author(s):
WANG DaoyuanQIAO BaopingSUN RukunXIN HangWANG Leiyang
Department of Urology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052
关键词:
前列腺癌前列腺特异性抗原前列腺特异性抗原密度Gleason评分临床分期
Keywords:
prostate cancerprostate specific antigen prostate specific antigen density Gleason scoreclinical stage
分类号:
R737.25
摘要:
目的:探讨前列腺特异性抗原(PSA)相关变数与前列腺癌病理分级及临床分期的关系。方法:回顾性分析125例经穿刺活检病理证实为前列腺癌患者的临床资料,采用Spearman相关分析探讨游离PSA(FPSA)、FPSA比率(F/TPSA)、PSA密度(PSAD)与Gleason评分及临床分期的关系。结果:FPSA与前列腺癌Gleason评分呈正相关(rS=0.499,P<0.001),与临床分期呈负相关(rS=-0.300,P<0.001);PSAD与前列腺癌Gleason评分呈正相关(rS=0.616,P<0.001),与临床分期无相关性(rS=-0.128,P=0.155);F/TPSA与前列腺癌Gleason评分呈弱相关(rS=0.182,P=0.042),与临床分期呈负相关(rS=-0.417,P<0.001)。结论:FPSA可作为前列腺癌病理分级和临床分期的参考指标;而PSAD可作为前列腺癌病理分级的参考指标,F/TPSA可作为前列腺癌临床分期的参考指标。
Abstract:
Aim:To explore the relationship between prostate specific antigen related variables and Gleason score and clinical stage in patients with prostate cancer.Methods:The clinical data from 125 cases of prostate cancer diagnosed by biopsies were collected,and the correlation of FPSA,F/TPSA and PSAD with Gleason score and clinical stage was analyzed.Results:FPSA was positively correlated with Gleason score(rS=0.499,P<0.001),but negatively correlated with clinical stage (rS=-0.300,P<0.001) for prostate cancer patients;PSAD was also positively correlated with Gleason score (rS=0.616,P<0.001),but not correlated with clinical stage (rS=-0.128,P=0.155) for prostate cancer patients; F/TPSA was negatively correlated with clinical stage (rS=-0.417,P<0.001),but weakly correlated with Gleason score (rS=0.182,P=0.042) for prostate cancer patients.Conclusion:FPSA could be used as a reference index in pathological grading and clinical staging for prostate cancer patients;PSAD could be used as a reference index in pathological grading and F/TPSA could be used as a reference index in clinical staging for prostate cancer patients.

参考文献/References:

[1]Jemal A,Siegel R,Ward E, et al.Cancer statistics 2007[J]. CA Cancer J Clin,2007,57(1):43
[2]David GB,John NE. Urologic surgical pathology [M].Boston:Mosby,1998:351
[3]Papsidero LD,Wang MC,Valenzuela LA, et al. A prostate specific antigen in sera of prostatic cancer patients[J].Cancer Res,1980,40(7):2428
[4]Poter JR, Brawer MK.Prostatic intraepithelial neoplasia and prostatespecific antigen[J].World J Urol,1993,11(4):196
[5]那彦群,孙光.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2011:56
[6]刘贺亮,王禾,杨晓剑,等.血清PSA、FPSAR与前列腺癌病理分级、临床分期的相关性研究[J].中华男科学杂志,2002,8(4):261
[7]Lerner SE, Jacobsen SJ, Lilja H,et al.Free,complexed, and total serum prostatespecific antigen concentrations and their proportions in predicting stage,grade,and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate[J]. Urology,1996,48:240
[8]Bangma CH, Krnase R, Bligenberg BG, et al. The freetototal serum prostate specific antigen ratio for staging prostate carcinoma[J]. J Urol,1997,157(2):544
[9]吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2009:1059
[10]Shinohara K,Wolf JS Jr,Narayan P,et al. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications[J].J Urol,1994,152(1):120
[11] Tanega SS,Hsu EI,Cheli CD, et al.Complexed prostatespecific antigen as a staging tool: results based on a multicenter prospective evaluation of prostatespecific antigen in cancer diagnosis[J].Urology,2002,60(4 Suppl):10
[12] Naya Y,Fritsche HA,Cheli CD,et al. Volume index of total,free,and complexed prostatespecific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer[J].Urology,2003,62(6):1058

相似文献/References:

[1]徐海亮)),贾占奎),杨锦建)#,等.经尿道姑息性前列腺汽化电切联合去势术及内分泌治疗晚期前列腺癌56例[J].郑州大学学报(医学版),2009,(03):668.
[2]张伟杰),别良玉),陆士新),等. 人前列腺癌组织中DNMT1、GSTP1和APC的表达*[J].郑州大学学报(医学版),2011,(03):370.
 ZHANG Weijie),BIE Liangyu),LU Shixin),et al. Expressions of DNMT1,GSTP1,and APC in prostate cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(04):370.
[3]王明臣)△,蒋薇薇),张善锋),等. DNA聚合酶β靶向siRNA对PC3细胞生物学行为的影响*[J].郑州大学学报(医学版),2011,(03):372.
 WANG Mingchen),JIANG Weiwei),ZHANG Shanfeng),et al. Effect of siRNA targeting DNA polymerase β on cellular biological behavior of PC3 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(04):372.
[4]张嵩),郝斌)#,李惠翔),等.AG490对前列腺癌DU145细胞增殖及STAT3信号通路相关蛋白表达的影响*[J].郑州大学学报(医学版),2012,(03):342.
 ZHANG Song),HAO Bin),LI Huixiang),et al.Effect of AG490 on DU145 cell proliferation and expressions of STAT3 signaling pathways related proteins[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(04):342.
[5]王婷),曾平)#,黄水平),等.微阵列数据分析和错误发现率*[J].郑州大学学报(医学版),2013,(01):59.
 WANG Ting,ZENG Ping,HUANG Shuiping,et al.Microarray data analysis and false discovery rate[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(04):59.
[6]姚杰,刘秉乾,魏金星#.人前列腺癌组织中PCA1及Ki67蛋白的表达*[J].郑州大学学报(医学版),2013,(02):198.
 YAO Jie,LIU Bingqian,WEI Jinxing.Expression of PCA1 and Ki67 proteins in prostate cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(04):198.
[7]单磊,郝建伟#,王向阳.LNCaP冻融抗原致敏的树突状细胞诱导的CTL对LNCaP细胞的杀伤作用*[J].郑州大学学报(医学版),2012,(06):824.
 SHAN Lei,HAO Jianwei,WANG Xiangyang.Effects of cytotoxicity T lymphocyte activated by dendritic cell loaded with LNCaP cell line frozenthawing antigen on LNCaP cell[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(04):824.
[8]朱海鹏△.萝卜硫素对LNCaP细胞增殖、周期、凋亡及IGFBP3、NFκB表达的影响[J].郑州大学学报(医学版),2014,(06):801.
 ZHU Haipeng.Effects of sulforaphane on proliferation, cell cycle and apoptosis of LNCaP and expressions of IGFBP3 and NFκB[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(04):801.
[9]杨德京,李沛寰,武玉东#.前列腺癌组织中ALKBH3和Bcl-xl蛋白的表达[J].郑州大学学报(医学版),2015,(04):493.
 YANG Dejing,LI Peihuan,WU Yudong.Expressions of ALKBH3 and Bclxl in prostate cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(04):493.
[10]施梦丽,杨 萍,杨 洋,等.血清TAM联合TPSA、FPSA/TPSA对前列腺癌的诊断价值[J].郑州大学学报(医学版),2019,(04):597.[doi:10.13705/j.issn.1671-6825.2018.11.135]
 SHI Mengli,YANG Ping,YANG Yang,et al.Diagnostic value of serum TAM combined with TPSA and FPSA/TPSA for prostate cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(04):597.[doi:10.13705/j.issn.1671-6825.2018.11.135]

备注/Memo

备注/Memo:
#通讯作者,男,1964年7月生,博士,主任医师,教授,研究方向:泌尿系肿瘤,Email:zhangyaling@zzu.edu.cn
更新日期/Last Update: 2012-08-14